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Abstract
MicroRNA-455-5p (miR-455-5p) seems to have an anti-inflammatory role in the immune system since its expression is induced
by IL-10 cytokine. Multiple sclerosis (MS) is a chronic demyelinating neurodegenerative disease of the central nervous system
that is caused by an autoimmune inflammatory attack against the myelin insulation of neurons. The expression level of miR-455-
5p and its role in MS pathogenesis has yet to be elucidated. We found that miR-455-5p expression was highly correlated with
disease severity inMS patients. miR-455-5p expression inversely correlates with its inflammatory-predicted targets (MyD88 and
REL) in relapse- and remitting-phase patients. Luciferase assays confirm that MyD88 and REL are direct targets of miR-455-5p.
This study represents the first report of the miR-455-5p acts as an anti-inflammatory role in MS, at least partially through
targeting MyD88 and REL. This study may provide important information for the use of miR-455-5p as a novel strategy to
improve the severity of disease and control inflammation and attack in MS patients.
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Introduction
Multiple sclerosis (MS) is one of the most common autoim-
mune disorders in young adults manifested by chronic inflam-
matory demyelination of the CNS. The disease is clinically
heterogeneous, with about 80% of patients developing the
relapsing-remitting MS (RR-MS) subtype (Du et al. 2009).
Although the cause of MS is still unknown, several epidemi-
ological and gene expression studies have been elucidated that
immune system is the greatest genetic contributor to disease
susceptibility. IFN-γ-producing Th1 cells and IL-17-producing
Th17 cells are main pro-inflammatory mediators of cellular
immunity that are responsible for autoimmune reactions in
CNS leading to axonal degeneration, demyelination, and
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ultimately irreversible tissue damage of patients with MS. In
fact, CNS autoimmunity is controlled by the balance between
inflammatory cytokines IL-17 and IFN-γ, and the opposing
regulatory cytokines IL-10 and the type I IFNs which produced
due to toll-like receptors (TLR) ligation (Guo 2016).
Today, recombinant interferon beta 1b and 1a (rIFN-b-1b,
rIFN-b-1a) are used to slow down disease progression both in
relapsing-remitting (RR) and secondary progressive (SP) MS
(Marziniak and Meuth 2014). One of the mechanisms by
which IFN-b-1b may exert its beneficial effects in MS is
through an impact on cytokine production and secretion such
as IL-10 (Ersoy et al. 2005). IL-10 expresses from Th0, Th1
and Th2 cells, B cells, and macrophages and has been consid-
ered to have a potential therapeutic role in experimental auto-
immune encephalomyelitis (EAE) mouse model and prevents
the development of the disease (Guo 2016).
MicroRNAs (miRNAs) have begun to emerge as an impor-
tant component in the development and progression of MS
(Wu and Chen 2016). miRNAs are small non-coding RNAs
that regulate their mRNA targets at the post-transcriptional
level through binding to complementary RNA sequences in
the 3′-untranslated region (3′UTR) of the targets (Kouhkan
et al. 2016; Kouhkan et al. 2013; Obeidi et al. 2016;
Tasharrofi et al. 2017; Zomorrod et al. 2018). The expression
of miRNAs in MS was first indicated in the cells derived
either fromMS patients’ blood samples or from active lesions.
Several miRNAs such as miR-155(Zhang et al. 2014), miR-
181a (Li et al. 2007), miR-326, miR-150, miR-146a
(O’Connell et al. 2010), miR-181b (Pekarsky et al. 2006),
miR-124, and miR-92a (Zhang et al. 2014) were identified
as important regulators for several aspects of immune cell
development and immune responses. miR-455-5p is one of
the miRNAs that are most highly induced in response to IL-
10 secretion. Its stimulation by IL-10 suggests that miR-455-
5p may have an unknown anti-inflammatory function in the
immune system (Cardwell and Weaver 2014).
In the present study, we examined the expression level of
miR-455-5p in PBMCs of RR-MS patients in relapse and
remitting phases. Furthermore, for the first time, in order to
clarify the anti-inflammatory role of miR-455-5p, its predicted




Blood samples were collected from 42 RR-MS patients in-
cluding 22 patients in relapsing and 20 patients in remitting
phases in the MS Clinic of Tehran Sina Hospital in the period
2016–2018. All MS patients fulfilled the McDonald’s criteria
and had Expanded Disability Status Scale (EDSS) of < 5.5
(Kurtzke 1983; Polman et al. 2011). The MS cohort consisted
of 60% females and 40% males. The healthy control samples
were also taken from the Tehran Sina Hospital. Patients hav-
ing newly diagnosed or not received any immunomodulatory
therapy 3 weeks before the blood withdrawal. Remitting-
phase patients were with no relapses at least in the last
3 months. Relapsing-phase patients were with a severe attack,
demonstrating any of the following symptoms: problems with
balance and coordination, trouble with vision, issues with
bladder, numb or tingling feelings (pins and needles), prob-
lems with memory and trouble concentrating that lasting more
than 24 h after the period of at least 30 days of improvement,
or stability.
Healthy subjects matched with cases in terms of gender and
age (mean age 40.7 years; range 25–56). All patient and con-
trol subjects signed an informed consent to participate in the
study.
Database prediction of miRNA targets
miR-455-5p targets were predicted using the TargetScan algo-
rithm (www.targetscan.org, version 5.1). Then, biological
processes and pathways of the given target list, including at
least 500 predicted targets, were analyzed using PANTHER
(www.pantherdb.org, version 7). In the Bonthology^ analysis
of PANTHER, Bpathway^ category was investigated and
targets in inflammation mediated by chemokine and
cytokine signaling pathway and toll receptor signaling
pathway that acquired the highest score in the TargetScan
were selected to continue the study including MyD88 and
REL.
PBMC isolation from blood and RNA extraction
Immediately after sampling, fresh blood was diluted with 2–
4 × the volume of the sterile phosphate-buffered saline (PBS).
Peripheral blood mononuclear cells (PBMCs) were isolated
by standard Ficoll (Ficoll-Paque PREMIUM GE Healthcare)
density-gradient centrifugation according to the manufac-
turer’s protocol. Finally, obtained PBMCs were washed twice
in sterile PBS.
Total RNA was purified from all obtained PBMCs using
TRIzol (Invitrogen) according to the manufacturer’s protocol.
Gene expression analysis
Total RNA reverse transcribed to cDNA using random
hexamers and M-MuLV Reverse Transcriptase (Promega)
for evaluation of the MyD88 and REL.
For miRNAs evaluation, total RNA first polyadenylated by
poly (A) polymerase. Then, reverse transcription was per-
formed using poly (A)-tailed total RNA, general RT primer,
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and reverse transcriptase according to the manufacturer’s pro-
tocol (BONmiR).
Real-time PCR was performed on ABI 157 PRISM 7500
real-time PCR System (Applied Biosystems) with 1 μl of
cDNA product, 1 × Quantitect SYBR Green PCR Master
Mix (Takara), and 0.5 μl of each forward and reverse primer.
Then, the reactions were incubated at 95 °C for 3 min, follow-
ed by 40 cycles of 95 °C for 30 s and 60 °C for 30 s. All of the
experiments were run in triplicate. The relative expression
level of mRNA and miRNA were analyzed and normalized
to endogenous expression of β-actin and SNORD47 RNA,
respectively, as an internal control using the 2−ΔΔCT method.
QRT-PCR primer sequences are listed as follows: miR-455-5p
F: GTG CCT TTG GAC TAC ATC G, SNORD47 F: ATC
ACT GTA AAA CCG TTC CA, MyD88 F: GAATGT GAC
TTC CAG ACC AA, MyD88 R: GAC AGT GAT GAA CCT
CAG GAT, REL F: GAATAA AGG CAG GAATCA ATC,
REL R: TTG GAG CAC GGT TGT CA, beta Actin F: CTT
CCT TCC TGG GCATG, and beta Actin R: GTC TTT GCG
GAT GTC CAC.
In target investigations, the mean of miR-455-5p and
SNORD47 Cts was determined in healthy samples and com-
pared with obtained Cts of each patient. Based on that, MS
patients were divided into two groups: a group that miR-455-
5p gene expression level was lower than healthy samples and
the other that miR-455-5p gene expression level was higher
than or equal to healthy samples. Subsequently, relative gene
expression of MyD88 and REL was determined using the
comparison of obtained Cts in MS patients with mean Cts in
normal samples.
Plasmids, viral vectors construction, and luciferase
assay
To determine whether miR-455-5p directly inhibits inflamma-
tory factors MyD88 and REL, luciferase assays were per-
formed. The human miR-455-5p locus on chromosome 9 with
its ∼ 500-base pair flanking sequences was PCR amplified
from genomic DNA and inserted into the pCDH-turbo GFP
expression vector. On the other hand, a genomic fragment
spanning the 3′UTR lengths of MyD88 and REL carrying
the putative miR-455-5p binding sites were cloned into
pSICHECK2 vectors. For the construction of Mut-miR-455-
5p, two mutations were created in the seed sequence of miR-
455-5p and mutated form was sub-cloned into the pCDH-
turbo GFP vector.
Human embryonic kidney 293 (HEK293) cells were seed-
ed in 96-well plates and transiently cotransfected with each of
the MyD88-3′UTR or REL-3′UTR luciferase vectors in com-
binat ion with pCDH-miR-455-5p plasmid using
Lipofectamine 2000 (Invitrogen) according to the manufac-
turer’s protocol. The pSICHECK2 empty vector and the
mutated miR-455-5p (Mut-miR-455-5p) were used as the
blank and the negative control, respectively.
Luciferase activity was assayed 48 h after transfection
using the dual-luciferase reporter assay system (Promega,)
and the Renilla luciferase signal normalized to the firefly lu-
ciferase signal activity for control of transfection efficiency.
All tests were run in triplicate. Three transfection assays were
performed to obtain statistically significant data.
Statistical analysis
QRT-PCR data analysis was carried out by theΔΔCTmethod
using REST 2009 software (Qiagen). Statistical analysis was
implemented by GraphPad Prism 6.02 (GraphPad Software
Inc., LaJolla, USA). All experiments were performed at least
three times, presented as mean ± SD and analyzed by
Student’s t test. ANOVA analysis was used to calculate the
differences of various comparisons. A value of p < 0.05 was
considered statistically significant.
Results
miR-455-5p downregulated in RR-MS patients
in relapse phase
miR-455-5p expression was investigated in PBMC samples
from RR-MS and control subjects. We found that miR-455-5p
expression was significantly lower in relapsing-phase patients
than in those of age-matched controls or patients in remitting
phase (Fig. 1a, b). The expression level of miR-455-5p was
downregulated up to 70% (p < 0.05) in relapsing-phase pa-
tients compared with the healthy samples. However, the ex-
pression level of miR-455-5p showed no substantial changes
between healthy subjects and remitting patient samples which
proposed a specific association of miR-455-5p expression
with the relapsing phase of MS.
miR-455-5p had an inverse relationship
with the expression level of MyD88 and REL in patient
samples
In order to determine the role of miR-455-5p in the pathology
of MS, analysis of conserved mRNA targets of miR-455-5p
(∼ 256 targets) was carried out using the TargetScan program
and then gene classification was performed by PANTHER.
Several different goals were identified for miR-455-5p in
MS-related pathways but the current project studies were
more focused on inflammation. So, MyD88 and REL were
selected to continue the study.
The mRNA expression levels of MyD88 and REL were
investigated in the relapsing and remitting patients. Patients
with relapsing MS had significantly higher MyD88 and REL
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expression (~ 1.7- and 5.6-fold, respectively, p < 0.05) but
those from patients with remitting MS did not. (Fig. 1c).
Next, to investigate whether MyD88 and REL expression
level is affected by miR-455-5p, MS patients in relapsing and
remitting phases were separated into two groups based on the
mean expression level of miR-455-5p in normal samples. The
first group had lower expression than the reference (≤ 1) and
the other group showed higher or equal expression levels
compared with the reference (≥ 1; p < 0.05). MyD88 and
REL showed increased median expression levels in the relaps-
ing patients expressing lower levels of miR-455-5p compared
to those expressing higher levels of miR-455-5p (~ 2.5- and
9.8-fold, compared to 0.85- and twofold respectively,
p < 0.05, Fig. 2a–d), Whereas the median expression level of
MyD88 and REL in remitting patients expressing lower levels
of miR-455-5p is high against those expressing higher levels
of miR-455-5p (~ 1.54- and 1.81-fold, compared to 0.47- and
0.53-fold respectively, p < 0.05, Fig. 2e–h).
Fig. 1 The expression levels of miR-455-5p and its predicted target genes
in samples. a Data from QRT-PCR analysis of miR-455-5p expression in
PBLs from normal controls (ctrl; n = 20) and MS patients in relapse
(n = 20) and remitting phase (n = 20). miR-455-5p expression was
significantly downregulated in relapse-phase patients. b Distribution of
MS patients in relapse and remitting phase according to miR-455-5p
expression. Data are normalized to those of controls and are presented
relative to expression of the SNORD47 using 2−ΔΔCt method. Data are
representative of three independent experiments. (*p < 0.05, versus
control; using Student’s t test). Horizontal lines represent the mean.
Circles represent the expression levels for individual patients. c
Expression level of miR-455-5p-predicted genes, REL andMyD88, were
significantly downregulated in relapse patients compared to the control
samples and remitting-phase patients. β-Actin was used as an internal
control. Columns and bars show mean of three different experiments
and SD respectively; (∗p < 0.05)
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Obtained results indicated that miR-455-5p expression lev-
el could affect the expression of predicted target genes, and
therefore it can be inferred that miR-455-5p can target MyD88
and REL.
miR-455-5p can directly target inflammatory targets
Given the main focus of the present study on inflammatory
pathways, we performed luciferase assay for inflammatory
targets, MyD88 and REL, to investigate the role of miR-
455-5p in this regard. According to TargetScan, there are
two predicted interaction site for miR-455-5p in the MyD88
3′UTR, whereas three sites are predicted to interact with miR-
455-5p in the REL 3′UTR, respectively (Fig. 3a). We cloned
two psiCHECK-2 plasmids driven by the cytomegalovirus
(CMV) basal promoter harboring the 224 nt and 210 nt from
REL and MyD88 3′UTRs, respectively, at the 3′ position of
the luciferase reporter gene.
In a parallel experiment, the conserved seed sequence
of miR-455-5p was specifically mutated (Fig. 3b). A
marked reduction in the luciferase/Renilla ratio was seen
for REL and MyD88 constructs transfected with wild type
of miR-455-5p but not with the control or empty vector
(Fig. 3c). Furthermore, the observed luciferase/Renilla re-
duction was abrogated when we cotransfected Mut-miR-
455-5p with two mutations at the seed sequence of miR-
455-5p.
Discussion
In all forms of MS, inflammation always exists when active
demyelination and neurodegeneration take place (Lassmann
2018; Leibowitz and Yan 2016). Immune-triggered inflamma-
tion due to releasing of inflammatory factors including reac-
tive oxygen or nitric oxide species (ROS and RNS),
excitotoxins as glutamate, and cytotoxic cytokines including
IFN-γ, TNF-α, IL-17, IL-21, IL-22, and IL-26 is critically
driving further damage and degeneration of CNS elements
inMS. So, modulators of inflammation are considered to have
valuable potential for clinical applications in the diagnosis or
treatment of this category of complicated immune disorders
(Chitnis and Weiner 2017; Matute et al. 2001).
IL-10 produced by innate immune cells as well as T and B
cells has been considered to have a potential therapeutic role
in MS because it promotes the development of an anti-
inflammatory cytokine pattern by inhibiting the IFN-γ pro-
duction of T cells and natural killer (NK) cells, particularly
via the suppression of IL-12 synthesis in accessory cells (Guo
2016). IL-10 suppresses the synthesis of many Th1-cell-
related cytokines (IFN-γ, TNF-a, TNF-b, IL-1, IL-2, IL-6),
and T cell proliferation and downregulates MHC class II ex-
pression on monocytes, and inhibits cytotoxic functions of
activated macrophages by inhibiting nitric oxide production
(Cunha et al. 1992; de Waal Malefyt et al. 1991).
On the other hand, recent studies demonstrate that IL-10
secretion also could constrain Th17 differentiation and func-
tion and could suppress Th17-mediated inflammation through
amplifying a negative regulatory loop of IL-10 production and
IL-10R signaling (Guo 2016).
A subsequent report indicated that miR-455-5p super in-
duced as result of TLR stimulation through the IL-10-
mediated anti-inflammatory response in mouse macrophages.
However, it remains to be determined whether miR-455-5p
plays a functional role in the IL-10-mediated anti-
inflammatory response in the human system (Cardwell and
Weaver 2014).
Thus, in this study, we sought to address the hypothesis that
whether miR-455-5p could involve in MS pathogenesis
through the act in an anti-inflammatory manner to selectively
suppress the expression of certain pro-inflammatory genes.
We have shown that miR-455-5p expression sharply down-
regulated in peripheral blood of patients in relapsing phase of
MS. Then, to obtain the correlation between miR-455-5p and
inflammation, we tried to identify putative targets of this
miRNA. By recruiting PANTHER algorithm, we found
MyD88 and REL genes that have the important role in inflam-
mation path. Next, patients were categorized based to the
miR-455-5p expression level. Our results indicated that high
expression level of miR-455-5p is correlated with lower ex-
pression levels of MyD88 and REL genes in relapse-phase
patients, thereby demonstrating its probable anti-
inflammatory effects in MS patients. We further confirmed
that predicted genes are direct targets of miR-455-5p by lucif-
erase assay.
MyD88, as an miR-455-5p-predicted target, is expressed
by dendritic cells, macrophages, and B lymphocytes and plays
a key role in the pathogenesis of EAE because MyD88
−/−mice were completely EAE resistant (Miranda-
Hernandez et al. 2011). MyD88 necessary for TLR-mediated
activation of the transcription factor nuclear factor-κB
(NF-κB) that promotes the expression of pro-inflammatory
cytokines and chemokines, such as IL-1 β, IL-6, IL-8, IL-
12, IL-23, and TNF-α, as well as the subsequent priming of
Th17 cells and their maintenance (Fig. 4a). Our results sug-
gested that downregulation of miR-455-5p in relapse MS pa-
tients leads to overexpression of MyD88 and subsequently
increase in the inflammation and severity of the disease
through promoting the differentiation and maintenance of
the Th17 cells and production of inflammatory cytokines.
Another predicted target is REL. REL is a canonical
NF-κB member expressed primarily in lymphoid tissues by
lymphoid and myeloid cells and plays different roles in im-
munity and inflammation. REL activity may enhance recruit-
ment of inflammatory cells and production of pro-
inflammatory mediators like IL-1β, IL-6, IL-8, IL-12, and
Immunogenetics
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TNF-a. Furthermore, antigen-presenting cells (APCs) require
REL for the production of IL-12 and IL-23, cytokines which
promote undifferentiated T cells (T0) to a T helper 1 (Th1) or
Th17 phenotype, respectively. Furthermore, REL controls the
expression of granulocyte/monocyte colony-stimulating fac-
tor (GM-CSF), a vital cytokine involved in EAE pathogenesis.
Also, REL appears to be required for Th17 differentiation
through activating the promoters of Th17-specific genes such
as Rorg (Hilliard et al. 2002; Liu et al. 2017; Mc Guire et al.
2013; Park et al. 2014; Ruan and Chen 2012; Tak and
Firestein 2001; Zhang et al. 2017). In the present study, an
inverse correlation between miR-455-5p and REL obviously
clears in the patients. This could be the other evidence that
miR-455-5p could exert an anti-inflammatory effect in MS
Fig. 3 MyD88 and REL are
regulated by miR-455-5p. a miR-
455-5p target sites reside at 3′
UTR of the MyD88 and REL
genes. The effects of miR-455-5p
on the expression level ofMyD88
and REL were evaluated using
luciferase assays. b Mut-miR-
455-5p was constructed by
creation of two mutations (it is
shown in bold and uppercase,
indicated with arrowhead) in seed
region and cloned in pCDH-turbo
GFP in the format of stem loop. c
HEK cells were cotransfected




normalized by the ratio of firefly
and Renilla luciferase activities.
miR-455-5p overexpression
inhibited luciferase activity of the
target genes. Ctrl is a blank
control group that was transfected
with the empty vector of
pSICHEK2. Mut-miR-455 is a
negative control that was
transfected with the mutated form
of miR-455-5p plasmid. Each bar
obtained from three independent
experiments with duplicated
samples in each experiment (n =
6). (*p < 0.05).
Fig. 2 Distribution of relapse- and remitting-phase patients according to
miR-455-5p expression. a Relapse-phase patients divided into two
groups based on miR-455-5p expression. b MyD88 and c-REL gene
expression in the relapse group, according to miR-455-5p level. c
Distribution of relative gene expression of MyD88 in relapse samples
according to miR-455-5p levels, (*p < 0.05). d Distribution of relative
gene expression of REL in relapse samples according to miR-455-5p
levels, (*p < 0.05). e Remitting-phase patients divided into two groups
based on miR-455-5p expression. fMyD88 and c-REL expression in the
remitting group, according to miR-455-5p level. gDistribution of relative
gene expression of MyD88 in remitting samples according to miR-455-
5p levels, (*p < 0.05). hDistribution of relative gene expression of c-REL
in remitting samples according to miR-455-5p levels, (*p < 0.05). Gene
expression levels of each patient indicated as a circle. The results are
relative gene expression after normalization with SNORD47 for miR-
455-5p and β-actin for MyD88 and c-REL using 2−ΔΔCt method.
Horizontal lines represent the mean
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patients via restriction of Th17 differentiation and prevention
of inflammatory cytokines production (Fig. 4b).
Collectively, we elucidated that miR-455-5p is downregu-
lated in relapsing MS patients compared with remitting-phase
patients. The exact underlying mechanism that is responsible
for the anti-inflammatory role of miR-455-5p has yet to be
identified in MS patients, but there is evidence that the direct
targeting of MyD88 and REL could be the reason for this
phenomenon. Overall, our findings introduce miR-455-5p as
one of the anti-inflammatory microRNAs enhances the
differentiation of Th17, so could be useful therapeutic ap-
proaches in getting a better control of inflammation and dis-
ease severity in MS patients.
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Fig. 4 Model of anti-
inflammatory role of miR-455-5p
through MyD88 and REL targets.
a miR-455-5p could inhibit
MyD88 that has direct role in the
production of IL-6 and IL-23 in
myeloid cells, which in turn
drives Th17 cell differentiation
and activation. In fact, Th17 cells
are not primed in the absence of
MyD88. b Another way through
which miR-455-5p exerts its
influence is via REL. REL not
only has a vital role in
differentiation of TH17 cells
through activation of RORγt, but
also involve in differentiation
induction of these cells through
production of IL-12 and IL-23
fromAPC cells. REL also directly
leads to inflammation through
production of IL-1, IL-2, IL-6, IL-
8, IL-12, and TNF-α
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